Skip to main content

Advertisement

SpringerLink
Log in

PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

Colorectal carcinoma (CRC) is the second most common and frequent cause of cancer-related deaths for men and women in the world. PIK3CA and PIK3CB that reverse multidrug resistance (MDR) can serve as predictive and prognostic markers as well as therapeutic targets for CRC treatment. In the present study, we showed that PIK3CA and PIK3CB are upregulated in CRCs and positively correlated with MDR-1, LRP, and GST-π. Long-term monitoring of 316 CRC patients showed that PIK3CA and PIK3CB were associated with poor survival time as shown by Kaplan-Meier analysis. Furthermore, we found that the downregulation of PIK3CA and PIK3CB reversed MDR; inhibited the capability of proliferation, migration, and invasion of CRC cells; and slowed down the CRC tumor growth in nude mice. Consistent with clinical observations, PIK3CA and PIK3CB significantly increase multidrug resistance of CRC cells in vivo. Together, these results suggest that PIK3CA and PIK3CB may be used as potential therapeutic drug targets for colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21:497–503.

    Article  CAS  PubMed  Google Scholar 

  2. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Siegel R et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.

    Article  PubMed  Google Scholar 

  4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  5. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.

    Article  CAS  PubMed  Google Scholar 

  6. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.

    Article  CAS  PubMed  Google Scholar 

  8. Rodriguez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des. 2006;12:4411–25.

    Article  CAS  PubMed  Google Scholar 

  9. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL-2 in human gastric cancer cell. Int J Cancer. 2008;123:372–9.

    Article  CAS  PubMed  Google Scholar 

  10. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29–86.

    Article  CAS  PubMed  Google Scholar 

  11. Miura Y, Ohnami S, Yoshida K, Ohashi M, Nakano M, Fukuhara M, et al. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett. 2005;218:53–62.

    Article  CAS  PubMed  Google Scholar 

  12. Trujillo MA, Oneal MJ, Davydova J, Bergert E, Yamamoto M, Morris 3rd JC. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer. Breast Cancer Res. 2009;11:R53.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol. 2006;208:299–318.

    Article  CAS  PubMed  Google Scholar 

  14. Samuels Y et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.

    Article  CAS  PubMed  Google Scholar 

  15. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008;415:97–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A. 2008;105:13057–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cui B, Tao J, Yang Y. Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer. Cell Biochem Biophys. 2012;62:47–54.

    Article  CAS  PubMed  Google Scholar 

  18. Zhu Y-F, Yu B-H, Li D-L, Ke H-L, Guo X-Z, Xiao X-Y. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol. 2012;18(28):3745–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wen F, He S, Sun C, Li T, Wu S. PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. Int J Clin Exp Pathol. 2014;7(11):8295–303.

    PubMed  PubMed Central  Google Scholar 

  20. TANG H, LIU X, WANG Z, et al. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res. 2011;1390:21–32.

    Article  CAS  PubMed  Google Scholar 

  21. D’Incalci M. Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch. Eur J Cancer. 2009;45(3):316–7.

    Article  PubMed  Google Scholar 

  22. Watanabe T. Chemoradiotherapy and adjuvant chemotherapy for rectal cancer. Int J Clin Oncol. 2008;13(6):488–97.

    Article  CAS  PubMed  Google Scholar 

  23. Saseinul S, RBerardi R, SSalvagni S, et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression amplification and NF-κB activation. Br J Can. 2008;98:71–6.

    Article  Google Scholar 

  24. Palumbo I, Piattoni S, Valentini V, Marini V, et al. Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. Int J Color Dis. 2014;29:31–41.

    Article  Google Scholar 

  25. Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes EE. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am J Clin Oncol. 2005;28(4):340–4.

    Article  CAS  PubMed  Google Scholar 

  26. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012;23:1518–25.

    Article  CAS  PubMed  Google Scholar 

  27. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Clin Oncol. 2010;28:1254–61.

    Article  CAS  Google Scholar 

  28. Zheng T, Wang J, Chen X, Liu LX. Role of microRNA in anticancer drug resistance. Int J Cancer. 2009;126:2–10.

    Article  Google Scholar 

  29. Xie X, Tang B, Zhou J, Gao Q, Zhang P, et al. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep. 2013;30:773–82.

    CAS  PubMed  Google Scholar 

  30. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008;99:121–8.

    CAS  PubMed  Google Scholar 

  31. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, et al. A drug targeting only p110α can block phosphoinositide 3-kinase signaling and tumour growth in certain cell types. Biochem J. 2011;438:53–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012;40:426–35.

    Article  CAS  PubMed  Google Scholar 

  33. El-Readi MZ, Hamdan D, Farrag N, et al. Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur J Pharmacol. 2010;626:139–45.

    Article  CAS  PubMed  Google Scholar 

  34. Barancík M, Bohácová V, Sedlák J, Sulová Z, Breier A. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci. 2006;29:426–34.

    Article  PubMed  Google Scholar 

  35. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene. 2002;21:1945–54.

    Article  CAS  PubMed  Google Scholar 

  36. García MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kB in murine lymphoma cell lines. Leuk Res. 2009;33(2):288–96.

    Article  PubMed  Google Scholar 

  37. Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book. 2013;33:395–401.

    Article  Google Scholar 

  38. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des. 2010;16:34–44.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Scientific and Technological Project of Shandong Province.

Author information

Authors and Affiliations

  1. The Department of Pathology, Binzhou Medical University Hospital, 256603, Binzhou, Shandong Province, China

    Shuhua Wu, Feifei Wen, Yangyang Li, Xiangqian Gao, Shuang He, Mengyao Liu, Xiangzhi Zhang & Dong Tian

Authors
  1. Shuhua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feifei Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yangyang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiangqian Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuang He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mengyao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiangzhi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dong Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong Tian.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, S., Wen, F., Li, Y. et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumor Biol. 37, 8799–8809 (2016). https://doi.org/10.1007/s13277-015-4691-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4691-5

Keywords

Search

Navigation